Q4 Earnings Estimate for Cingulate Issued By HC Wainwright

Cingulate Inc. (NASDAQ:CING) – Research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Cingulate in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($1.05) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. HC Wainwright also issued estimates for Cingulate’s Q1 2025 earnings at ($1.05) EPS, Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.58) EPS and Q4 2025 earnings at ($0.56) EPS.

CING has been the topic of several other research reports. Roth Capital raised shares of Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Maxim Group upgraded Cingulate from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Roth Mkm initiated coverage on Cingulate in a research note on Friday, January 10th. They set a “buy” rating and a $12.00 price objective on the stock.

Cingulate Stock Performance

Shares of CING opened at $4.55 on Monday. Cingulate has a 12 month low of $1.80 and a 12 month high of $58.32. The stock’s 50-day moving average is $4.58 and its two-hundred day moving average is $4.59.

Cingulate (NASDAQ:CING) last issued its earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($2.22) by $0.39.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cingulate stock. Jane Street Group LLC bought a new stake in Cingulate Inc. (NASDAQ:CING) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 21,031 shares of the company’s stock, valued at approximately $106,000. Jane Street Group LLC owned about 0.66% of Cingulate as of its most recent SEC filing. 41.31% of the stock is currently owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.